Tear Sheet

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Tear Sheet

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. 

Press Releases
Date Title
06/29/20 Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program
06/24/20 Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities
06/22/20 New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
06/04/20 Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
06/02/20 Alkermes Response to Current Events
Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Filing date Description

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Initial filing by director officer or owner of more than ten percent.

Statement of changes in beneficial ownership of securities